Clinical trial
A Study In Patients With Type 2 Diabetes Mellitus
NCT00256867 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00256867 |
|---|---|
| Title | A Study In Patients With Type 2 Diabetes Mellitus |
| Official title | A 16 Week Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of a New Medication (GSK523338) to Lower LDL-c and HbA1c in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | GSK523338 |
| Enrollment | 369 |
| Start date | Aug 18, 2005 |
| Primary completion | Oct 31, 2006 |
| Completion | Oct 31, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Jul 2, 2018 |
| Countries | Australia, Canada, Mexico, Philippines, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: